Table 1.
miRNA expression and clinicopathological characteristics
| Number of cases (n) | |
|---|---|
| (A) Clinical backgrounds of 75 cases | |
| Age | ≥65 years, n = 41; <65 years, n = 34 |
| Gender | Male, n = 50; female, n = 25 |
| Smoking | Smoker, n = 49; nonsmoker, n = 25; unknown, n = 1 |
| Histology | Adenocarcinoma, n = 61; squamous cell carcinoma, n = 11Adenosquamous carcinoma, n = 1; pleomorphic carcinoma, n = 2 |
| Tumor size | T1, n = 35; T2–4, n = 40 |
| miR-139 low (n) | miR-139 high (n) | P value | |
|---|---|---|---|
| (B) miRNA expression and clinicopathological characteristics (univariate analysis) | |||
| Tumor size | |||
| T1 | 22 | 13 | 0.84 |
| T2–4 | 26 | 14 | |
| Distant lymph node metastasis | |||
| N0–1 | 30 | 23 | 0.038* |
| N2 | 18 | 4 | |
| Lymphatic and venous invasion | |||
| Both positive | 17 | 3 | 0.022* |
| Others | 31 | 24 | |
| EGFR mutation | |||
| Positive | 16 | 9 | 0.89 |
| Negative | 30 | 18 | |
| Odds ratio (95% confidential interval) | P value | |
|---|---|---|
| (C) miRNA expression and distant lymph node metastasis (multivariate analysis) | ||
| miR-139 expression (low or high) | 3.993 (1.1–14.488) | 0.035* |
| Tumor size (T2–4 or T1) | 6.629 (1.89–23.249) | 0.003* |
| Odds ratio (95% confidential interval) | P value | |
|---|---|---|
| (D) miRNA expression and local invasiveness (multivariate analysis) | ||
| miR-139 expression low or high) | 5.415 (1.362–21.529) | 0.016* |
| Smoking (smoker or nonsmoker) | 4.749 (1.184–19.056) | 0.028* |
Asterisks (*) indicate statistical significance (p<0.05).